患者因素与慢阻肺和哮喘早期识别及治疗的临床疗效
本研究基于Undiagnosed COPD and Asthma Population试验的508例新诊断慢阻肺或哮喘患者,随机接受呼吸科医生干预或常规护理。结果显示基线疾病负担较高者从早期诊断治疗中获益更大,高负担组71%患者12个月内CAT评分改善≥2分,低负担组为47%(OR 2.78,95%CI 1.90-4.07,P<0.001);哮喘与慢阻肺患者获益相似,但哮喘患者从呼吸科医生主导的护理中获益更多。
要点
- 基线疾病负担较高的新诊断慢阻肺或哮喘患者从早期诊断治疗中获益更大。
- 高负担组71%患者12个月内CAT评分改善≥2分,低负担组为47%。
- 哮喘患者从呼吸科医生主导的护理中获益大于慢阻肺患者。
核心结论
- 诊断时疾病负担更高的患者从早期诊断和治疗中获益更多。
- 哮喘患者较慢阻肺患者更倾向于从呼吸科医生主导的护理中获益。
研究设计与样本
- 基于Undiagnosed COPD and Asthma Population试验,共508例新诊断慢阻肺或哮喘患者随机接受呼吸科医生干预或常规护理。
- 采用圣乔治呼吸问卷(SGRQ)和慢阻肺评估测试(CAT)基线评分中位数分割定义低和高疾病负担,并使用最小临床重要差异阈值定义显著应答。
主要发现
- 高疾病负担组71%患者12个月内CAT评分改善≥2分,低疾病负担组为47%(OR 2.78,95%CI 1.90-4.07,P<0.001)。
- SGRQ和FEV1改善也观察到类似结果。
- 哮喘与慢阻肺患者对早期诊断和治疗的反应相似。
- 随机接受呼吸科医生主导护理的哮喘患者1年内CAT评分、SGRQ评分、36项简表评分和FEV1改善大于接受初级保健者。
- 慢阻肺患者无论由呼吸科医生还是初级保健提供者管理,改善程度相似。
关键数值与推荐
- 高疾病负担组71%患者12个月内CAT评分改善≥2分,低疾病负担组47%(OR 2.78,95%CI 1.90-4.07,P<0.001)。
临床怎么用
- 对新诊断的慢阻肺或哮喘患者,应优先识别疾病负担较高者并尽早给予诊断和治疗。
- 哮喘患者可能从呼吸科医生主导的护理中获益更多。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: The Undiagnosed COPD and Asthma Population trial showed that early diagnosis and treatment of asthma and chronic obstructive pulmonary disease (COPD) by pulmonologists improved healthcare use, respiratory symptoms, and quality of life. Objectives: To determine if the benefits of early diagnosis and treatment were greater in individuals with more advanced disease or in individuals with asthma as opposed to COPD. We also assessed whether pulmonologist-directed care benefited asthma and COPD subgroups equally. Methods: Case finding was used to identify adults with undiagnosed chronic respiratory symptoms in the community. A total of 508 newly diagnosed participants with COPD or asthma were randomized to receive pulmonologist-care intervention or usual care. Low and high disease burden categories for the St. George's Respiratory Questionnaire (SGRQ) and COPD Assessment Test were defined using a median-split of baseline scores, and minimal clinically important difference thresholds were used to define significant responses. Benefits of pulmonologist care were assessed by evaluating treatment effects within subgroups and by assessing treatment-by-subgroup interactions. Measurements and Main Results: Patients with higher disease burden at diagnosis were more likely to benefit from early diagnosis and treatment compared with those with lower disease burden. A total of 71% of those with high disease burden showed an improvement in COPD Assessment Test score by ⩾2 points over 12 months compared with 47% with low disease burden (odds ratio, 2.78; 95% confidence interval, 1.90-4.07; P < 0.001). Similar results were seen for SGRQ and FEV1 improvements. In contrast, responses to early diagnosis and treatment were similar for those with asthma versus COPD. Individuals with asthma randomized to undergo pulmonologist-directed care showed greater 1-year improvements in COPD Assessment Test score, SGRQ score, 36-item Short Form score, and FEV1 compared with individuals randomized to receive primary care. However, individuals with COPD experienced similar improvements regardless of whether their treatment was managed by a pulmonologist or primary care provider. Treatment-by-disease interaction terms were not statistically significant. Conclusions: Patients with greater disease burden who exhibited more advanced and symptomatic asthma and COPD at the time of diagnosis benefited more from earlier diagnosis and treatment. Patients with asthma tended to derive greater benefit from pulmonologist-directed care than patients with COPD.
引用
- Tardif A, Whitmore GA, Vandemheen KL, et al. Patient Factors and Clinical Efficacy of Early Identification and Treatment of Chronic Obstructive Pulmonary Disease and Asthma. Am J Respir Crit Care Med. 2025. PMID: 41056133. doi:10.1164/rccm.202505-1260OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。